FY2023 FINANCIAL RESULTS
ENDED MARCH 31, 2024

from the beginning

FY2023 FINANCIAL RESULTS ENDED MARCH 31, 2024

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

I. FY2023 Consolidated Financial Results

• FY2023 FINANCIAL RESULTS: OVERVIEW

• FY2023 FINANCIAL RESULTS

• FY2023 FINANCIAL RESULTS: MAIN PRODUCTS

• FY2023 FINANCIAL RESULTS: COST ITEMS

II. Initiatives for Sustainable Growth

• INITIATIVES FOR SUSTAINABLE GROWTH: OVERVIEW OF QUARTERLY UPDATES

• XTANDI AND STRATEGIC PRODUCTS: FY2023 KEY EVENTS

• PROGRESS IN FOCUS AREA APPROACH: CURRENT STATUS OF PROJECTS IN CLINICAL TRIAL

• PROGRESS IN FOCUS AREA APPROACH: NEW CLINICAL PROGRAMS

• REVIEW OF CSP2021 SO FAR

III. FY2024 Forecast CSP2021 Outlook

• FY2024 FORECAST: BACKGROUND

• FY2024 FORECAST: XTANDI, PADCEV, XOSPATA, VYLOY

• FY2024 FORECAST: VEOZAH, IZERVAY

• XTANDI AND STRATEGIC PRODUCTS: FY2024 KEY EXPECTED EVENTS

• FOCUS AREA APPROACH: OUTLOOK

• CHANGE IN DEFINITION OF CORE BASIS FROM FY2024

• FY2024 FORECAST

• CSP2021: LATEST OUTLOOK

APPENDIX

• XTANDI & XOSPATA: BUSINESS UPDATE

• PADCEV & VYLOY: BUSINESS UPDATE

• VEOZAH: BUSINESS UPDATE

• IZERVAY: BUSINESS UPDATE (US)

• FY2023 ACTUAL: FX RATE

• FY2024 FORECAST: FX RATE & FX SENSITIVITY

• BALANCE SHEET & CASH FLOW HIGHLIGHTS

• BALANCE OF BONDS AND BORROWINGS HIGHLIGHTS

• CORE BASIS PERFORMANCE: CHANGES IN DEFINITIONS AND CONTEXT

• MAIN INTANGIBLE ASSETS (AS OF FY2023 END)

• CAPITAL ALLOCATION

• ROBUST PIPELINE OF ASTELLAS

• PROGRESS IN OVERALL PIPELINE

• 37 XTANDI AND STRATEGIC PRODUCTS: POTENTIAL PEAK SALES(AS OF APR 2024)

• XTANDI AND STRATEGIC PRODUCTS: STATUS UPDATE

• ENZALUTAMIDE (1/2): ANDROGEN RECEPTOR INHIBITOR

• ENZALUTAMIDE (2/2): PHASE 3 STUDY DATA BY DISEASE STAGE

• ENFORTUMAB VEDOTIN (EV) (1/4): NECTIN-4 TARGETED ADCOVERALL UC PROGRAM

• ENFORTUMAB VEDOTIN (EV) (2/4): CLINICAL STUDIES

• ENFORTUMAB VEDOTIN (EV) (3/4): STUDY DATA BY DISEASE STAGE OF UC

• ENFORTUMAB VEDOTIN (EV) (4/4): FUTURE OUTLOOK

• GILTERITINIB: FLT3 INHIBITOR

• ZOLBETUXIMAB: ANTI-CLAUDIN 18.2 MONOCLONAL ANTIBODY

• FEZOLINETANT: NK3 RECEPTOR ANTAGONIST

• AVACINCAPTAD PEGOL (ACP): COMPLEMENT C5 INHIBITOR / PEGYLATED RNA APTAMER

• ON THE FOREFRONT OF HEALTHCARE CHANGE

Questions

• Questions 1

• Questions 2

• Questions 3

• Questions 4

• Questions 5

• Questions 6

• Questions 7

• Questions 8